The Stevanato Group S.p.A, a provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, entered into a collaboration with contract development and manufacturing organization (CDMO), Recipharm.

Under the agreement, Stevanato will support the development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.

Stevanato will provide and manufacture its glass pre-fillable syringe Alba assembled with the Integrated Spray Module (ISM) of Recipharm’s soft mist inhaler technology, the Pre-Filled Syringe Inhaler (PFSI).

Bernhard Muellinger, general manager and chief operational officer at Resyca, a joint venture between Recipharm and Medspray, said, “By leveraging Stevanato Group’s integrated capabilities, from plastic injection molding and assembly capabilities to comprehensive scientific and analytical support services, we will be able to offer a turnkey solution, and accelerate and de-risk our pharmaceutical customers’ development programs. This is particularly true for novel inhaled biological products.”

Mauro Stocchi, chief brand officer of Stevanato Group, said, “Biopharma companies are advancing patient care with new, innovative treatments, particularly in biologics and mRNA therapies. These products require specialized, high-performance drug containment systems, like our Alba syringe platform, together with patient-centric drug delivery devices like the PFSI. Thanks to our integrated end-to-end capabilities we are able to support our customers at scale with a comprehensive system solution.”

Stevanato Group’s Alba syringes feature an internal coating based on silicone oil, which is cross-linked with the glass surface, thereby minimizing sub-visible particle release and aiming to ensure superior performance during delivery.

According to the company, the combination of the Alba syringe and Recipharm’s innovative soft mist inhaler technology delivers sensitive drug products more efficiently to the respiratory airways and provides biopharma companies with a containment solution featuring enhanced stability and safety.

Recipharm’s focus will be on the design and manufacture of the spray technology, the inhalation device, and the fill and finish of the product.

Recipharm’s soft mist inhaler (PFSI) is developed, manufactured, and licensed by Resyca and is supplied as a pre-filled and ready-to-use inhalation device.